Perivascular stem cell niche in head and neck cancer

Cancer Letters

Volumn 338, Issue 1, 2013, Pages 41-46

  Ritchie, Kathryn E ^a   Nör, Jacques E ^a,b,c  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Angiogenesis; Oral cancer; Stemness; Tumor initiation; Tumor microenvironment; Tumorigenesis

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD133 ANTIGEN; HERMES ANTIGEN; TUMOR MARKER;

CANCER STEM CELL; CANCER STEM CELL TRANSPLANTATION; CANCER THERAPY; CELL POPULATION; CELL RENEWAL; CELL SURVIVAL; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; DISEASE MARKER; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; PATIENT CARE; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; STEM CELL NICHE; STEM CELL TRANSPLANTATION; TUMOR MICROENVIRONMENT;

EID: 84882830371     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.025     Document Type: Review

References (60)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011, 61:69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA: A Cancer Journal for Clinicians 2012, 62:10-29.
3. NCI, Cancer Trends Progress Report 2009/2010 Update.
4. Prince M.E., Sivanandan R., Kaczorowski A., Wolf G.T., Kaplan M.J., Dalerba P., Weissman I.L., Clarke M.F., Ailles L.E. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proceedings of the National academy of Sciences of the United States of America 2007, 104:973-978.
5. Krishnamurthy S., Dong Z., Vodopyanov D., Imai A., Helman J.I., Prince M.E., Wicha M.S., Nör J.E. Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Research 2010, 70:9969-9978.
6. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
7. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
8. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine 1997, 3:730-737.
9. Clarke M.F., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., Visvader J., Weissman I.L., Wahl G.M. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Research 2006, 66:9339-9344. (Baltimore).
10. Lu J., Fan T., Zhao Q., Zeng W., Zaslavsky E., Chen J.J., Frohman M.A., Golightly M.G., Madajewicz S., Chen W.-T. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. International Journal of Cancer 2010, 126:669-683.
11. Virchow R. Die Cellularpathologie in ihrer Begrundung auf physiologische und pathologische Gewebelehre 1858, August Hirschwald, Berlin.
12. Furth J., Kahn M.C. The transmission of leukemia in mice with a single cell. The American Journal of Cancer 1937.
13. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
14. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences 2003, 100:3983-3988.
15. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Research 2007, 67:1030-1037. (Baltimore).
16. Dalerba P., Dylla S.J., Park I.-K., Liu R., Wang X., Cho R.W., Hoey T., Gurney A., Huang E.H., Simeone D.M., Shelton A.A., Parmiani G., Castelli C., Clarke M.F. Phenotypic characterization of human colorectal cancer stem cells. Proceedings of the National academy of Sciences of the United States of America 2007, 104:10158-10163.
17. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research 2005, 65:10946-10951. (Baltimore).
18. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Research 2003, 63:5821-5828. (Baltimore).
19. Ishizawa K., Rasheed Z.A., Karisch R., Wang Q., Kowalski J., Susky E., Pereira K., Karamboulas C., Moghal N., Rajeshkumar N.V., Hidalgo M., Tsao M., Ailles L., Waddell T.K., Maitra A., Neel B.G., Matsui W. Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 2010, 7:279-282.
20. Quintana E., Shackleton M., Foster H.R., Fullen D.R., Sabel M.S., Johnson T.M., Morrison S.J. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010, 18:510-523.
21. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
22. Deleyrolle L.P., Harding A., Cato K., Siebzehnrubl F.A., Rahman M., Azari H., Olson S., Gabrielli B., Osborne G., Vescovi A., Reynolds B.A. Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain 2011, 134:1331-1343.
23. McCord A.M., Jamal M., Williams E.S., Camphausen K., Tofilon P.J. CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clinical Cancer Research 2009, 15:5145-5153.
24. Woodward W.A., Chen M.S., Behbod F., Alfaro M.P., Buchholz T.A., Rosen J.M. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proceedings of the National academy of Sciences of the United States of America 2007, 104:618-623.
25. Baumann M., Krause M. CD44: a cancer stem cell related biomarker with predictive potential for radiotherapy. Clinical Cancer Research 2010, 16:5091-5093.
26. Chikamatsu K., Ishii H., Takahashi G., Okamoto A., Moriyama M., Sakakura K., Masuyama K. Resistance to apoptosis-inducing stimuli in CD44+ head and neck squamous cell carcinoma cells. Head and Neck 2011, 336-343.
27. Faber A., Barth C., Hörmann K., Kassner S., Schultz J.D., Sommer U., Stern-Straeter J., Thorn C., Goessler U.R. CD44 as a stem cell marker in head and neck squamous cell carcinoma. Oncology Reports 2011, 26:321-326.
28. Clay M.R., Tabor M., Owen J.H., Carey T.E., Bradford C.R., Wolf G.T., Wicha M.S., Prince M.E. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head and Neck 2010, 32:1195-1201.
29. Tang A.L., Hauff S.J., Owen J.H., Graham M.P., Czerwinski M.J., Park J.J., Walline H., Papagerakis S., Stoerker J., McHugh J.B., Chepeha D.B., Bradford C.R., Carey T.E., Prince M.E. UM-SCC-104: a new human papillomavirus-16-positive cancer stem cell-containing head and neck squamous cell carcinoma cell line. Head and Neck 2011.
30. Campos M.S., Neiva K.G., Meyers K.A., Krishnamurthy S., Nör J.E. Endothelial derived factors inhibit anoikis of head and neck cancer stem cells. Oral Oncology 2012, 48:26-32.
31. Sano D., Myers J. Metastasis of squamous cell carcinoma of the oral tongue. Cancer and Metastasis Reviews 2007, 26:645-662.
32. Gao L., Yan L., Lin B., Gao J., Liang X., Wang Y., Liu J., Zhang S., Masao I. Enhancive effects of Lewis y antigen on CD44-mediated adhesion and spreading of human ovarian cancer cell line RMG-I. Journal of Experimental & Clinical Cancer Research 2011, 30:15.
33. Wang S.J., Bourguignon L.Y.W. Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. The American Journal of Pathology 2011, 178:956-963.
34. Joshua B., Kaplan M.J., Doweck I., Pai R., Weissman I.L., Prince M.E., Ailles L.E. Frequency of cells expressing CD44, a head and neck cancer stem cell marker: correlation with tumor aggressiveness. Head and Neck 2012, 34:42-49.
35. Judd N.P., Winkler A.E., Murillo-Sauca O., Brotman J.J., Law J.H., Lewis J.S., Dunn G.P., Bui J.D., Sunwoo J.B., Uppaluri R. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Research 2012, 72:365-374. (Baltimore).
36. Molofsky A.V., Pardal R., Iwashita T., Park I.-K., Clarke M.F., Morrison S.J. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003, 425:962-967.
37. Wei X.D., Zhou L., Cheng L., Tian J., Jiang J.J., MacCallum J. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line. Head and Neck 2009, 31:94-101.
38. Chiou S.-H., Yu C.C., Huang C.Y., Lin S.C., Liu C.J., Tsai T.H., Chou S.H., Chien C.S., Ku H.H., Lo J.F. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clinical Cancer Research 2008, 14:4085-4095.
39. Zhang Q., Shi S., Yen Y., Brown J., Ta J.Q., Le A.D. A subpopulation of CD133+ cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Letters 2010, 289:151-160.
40. Ma I., Allan A. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Reviews and Reports 2011, 7:292-306.
41. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
42. Rasper M., Schäfer A., Piontek G., Teufel J., Brockhoff G., Ringel F., Heindl S., Zimmer C., Schlegel J.R. Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity. Neuro-Oncology 2010, 12:1024-1033.
43. Chen C., Wei Y., Hummel M., Hoffmann T.K., Gross M., Kaufmann A.M., Albers A.E. Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS ONE 2011, 6:e16466.
44. Goodell M.A., Brose K., Paradis G., Conner A.S., Mulligan R.C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. Journal of Experimental Medicine 1996, 183:1797-1806.
45. Zhang P., Zhang Y., Mao L., Zhang Z., Chen W. Side population in oral squamous cell carcinoma possesses tumor stem cell phenotypes. Cancer Letters 2009, 277:227-234.
46. Yanamoto S., Kawasaki G., Yamada S.-i., Yoshitomi I., Kawano T., Yonezawa H., Rokutanda S., Naruse T., Umeda M. Isolation and characterization of cancer stem-like side population cells in human oral cancer cells. Oral Oncology 2011, 47:855-860.
47. Morrison S.J., Spradling A.C. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell 2008, 132:598-611.
48. Borovski T., De Sousa E., Melo F., Vermeulen L., Medema J.P. Cancer stem cell niche: the place to be. Cancer Research 2011, 71:634-639. (Baltimore).
49. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Oh E.Y., Gaber M.W., Finklestein D., Allen M., Frank A., Bayazitov I.T., Zakharenko S.S., Gajjar A., Davidoff A., Gilbertson R.J. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
50. Shen R., Ye Y., Chen L., Yan Q., Barsky S.H., Gao J.-X. Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS ONE 2008, 3:e1652.
51. Nör J.E., Peters M.C., Christensen J.B., Sutorik M.M., Linn S., Khan M.K., Addison C.L., Mooney D.J., Polverini P.J. Engineering and characterization of functional human microvessels in immunodeficient mice. Laboratory Investigation 2001, 81:453-463.
52. Neiva K.G., Zhang Z., Miyazawa M., Warner K.A., Karl E., Nör J.E. Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia (New York, N.Y.) 2009, 11:583-593.
53. Folkins C., Man S., Xu P., Shaked Y., Hicklin D.J., Kerbel R.S. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Research 2007, 67:3560-3564.
54. Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000, (cited 03.30.12). http://clinicaltrials.gov.
55. Conley S.J., Gheordunescu E., Kakarala P., Newman B., Korkaya H., Heath A.N., Clouthier S.G., Wicha M.S. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proceedings of the National academy of Sciences of the United States of America 2012, 109:2784-2789.
56. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer 2008, 8:592-603.
57. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., Campbell L.L., Polyak K., Brisken C., Yang J., Weinberg R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
58. Paez-Ribes M., Allen E., Hudock J., Takeda T., Okuyama H., Vinals F., Inoue M., Bergers G., Hanahan D., Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
59. Sansone P., Storci G., Tavolari S., Guarnieri T., Giovannini C., Taffurelli M., Ceccarelli C., Santini D., Paterini P., Marcu K.B., Chieco P., Bonafè M. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. Journal of Clinical Investigation 2007, 117:3988-4002.
60. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., Wicinski J., Cabaud O., Charafe-Jauffret E., Birnbaum D., Guan J.L., Dontu G., Wicha M.S. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. Journal of Clinical Investigation 2010, 120:485-497.